ISM 8001
Alternative Names: ISM-8001Latest Information Update: 12 Jul 2024
At a glance
- Originator InSilico Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Jul 2024 ISM 8001 is available for licensing as of 05 Apr 2024. https://insilico.com/pipeline_target_fgfr2/3
- 05 Apr 2024 Preclinical trials in Solid tumours in USA (PO), prior to April 2024
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)